SCHEMBL6432637

SCHEMBL6432637

NN=C(c1ccccc1O)c1nc2nonc2nc1Nc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.35
MAPT P10636 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
GAA P10253 2/20 0.34
RECQL P46063 1/20 0.34
POLB P06746 1/20 0.34
DHFR P00374 1/20 0.34
PIM1 P11309 2/20 0.32
DHODH Q02127 1/20 0.32
MEN1 O00255 4/20 0.32
KMT2A Q03164 4/20 0.32
LMNA P02545 3/20 0.32
HTT P42858 3/20 0.32
KDM4E B2RXH2 3/20 0.32
HPGD P15428 2/20 0.32
HSD17B10 Q99714 1/20 0.32
MAPK1 P28482 2/20 0.32
BCL6 P41182 1/20 0.32
GSTA1 P08263 1/20 0.32
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6432628 1.00 TP53 (0.35) TP53MAPTSMN1; SMN2GAARECQL
SCHEMBL6421060 0.91 MAPT (0.44) TP53MAPTSMN1; SMN2GAARECQL
SCHEMBL6421067 0.91 MAPT (0.44) TP53MAPTSMN1; SMN2GAARECQL
SCHEMBL6414923 0.89 CYP3A4 (0.38) TP53MAPTSMN1; SMN2GAARECQL
SCHEMBL6414910 0.89 CYP3A4 (0.38) TP53MAPTSMN1; SMN2GAARECQL
SCHEMBL6415753 0.88 TP53 (0.41) TP53MAPTSMN1; SMN2POLBPIM1
SCHEMBL6415756 0.88 TP53 (0.41) TP53MAPTSMN1; SMN2POLBPIM1
SCHEMBL6419692 0.87 DHODH (0.42) TP53MAPTSMN1; SMN2GAARECQL
SCHEMBL6419681 0.87 DHODH (0.42) TP53MAPTSMN1; SMN2GAARECQL
SCHEMBL6416319 0.87 TP53 (0.42) TP53MAPTSMN1; SMN2POLBPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 TP53 4485/4885MAPT 4420/4885SMN1; SMN2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.